Molecular structure of RHD negative

• US 9,217,181 B2
• Filed: 02/23/2009
• Issued: 12/22/2015
• Est. Priority Date: 11/02/1999
• Status: Expired due to Term

• Current Assignee: DRK-Blutspendedienst Baden Württemberg-Hessen gemeinnützige GmbH
• Original Assignee: DRK-Blutspendedienst Baden Württemberg-Hessen gemeinnützige GmbH
• Inventors: Flegel, Willy A., Wagner, Franz F.
• Primary Examiner(s): Mummert, Stephanie K
• Assistant Examiner(s): PRIEST, AARON A
• Application Number:
  US12/390,982
• Publication Number:
  US 20110172406A1
• Time in Patent Office: 2,493 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12N 15/52 Genes encoding for enzymes or proenzymes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention relates to a nucleic acid molecular structure representing the Rhesus genes locus comprising the RHD, SMP1 and RHCE genes and/or the Rhesus box(es), preferably the hybrid Rhesus box, the upstream Rhesus bar and/or the downstream Rhesus box. Furthermore, the invention relates to a process for the specific detection of the common RHD negative haplotypes. The invention further relates to the detection of RHD positive hyplotypes in D-negative individuals. Various mutations in the RHD gene have been identified that allow for the development of diagnostic tools. The invention also relates to oligonucleotides, that specifically hybridize to the hybrid box, preferably the breakpoint or breakpoint region or to the upstream and downstream Rhesus boxes. Additionally, the invention relates to kits comprising or employing the above recited compounds of the invention.

Claims

1. An amplification product carrying a breakpoint region located in SEQ ID NOS 22-24, and/or a breakpoint region located in SEQ ID NOS 25-27, or both breakpoint regions, wherein the amplification product is labelled with a radioactive marker, or a fluorescent, phosphorescent, chemiluminescent or enzymatic label, or wherein the amplification product is fixed to a solid support.

2. The amplification product of claim 1, wherein the breakpoint region located in SEQ ID NOS 22-24 and/or SEQ ID NOS 25-27 encodes a polypeptide having antigen C reactivity.

3. The amplification product of claim 1, wherein the amplification product is labelled with the radioactive marker, or the fluorescent, phosphorescent, chemiluminescent or enzymatic label.

4. The amplification product of claim 1, wherein the amplification product is fixed to a solid support.

10. The amplification product of claim 1, wherein the solid support comprises a chip.

11. The amplification product of claim 1, comprising the breakpoint region of SEQ ID NO:

23 or SEQ ID NO;

26.

5. A gel comprising an amplification product carrying a breakpoint region located in SEQ ID NOS 22-24, and/or a breakpoint region located in SEQ ID NOS 25-27, or both breakpoint regions.

6. The gel of claim 5, wherein the breakpoint region located in SEQ ID NOS 22-24 and/or SEQ ID NOS 25-27 encodes a polypeptide having antigen C reactivity.

7. The gel of claim 5, wherein the gel comprises an electrophoresis gel.

8. The gel of claim 5, wherein the gel comprises an agarose gel.

9. The gel of claim 5, wherein the gel comprises a polyacrylamide gel.

12. The gel of claim 5, wherein the amplification product comprises the breakpoint region of SEQ ID NO:

23 or SEQ ID NO;

26.